Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Interest Receivables (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Change in Interest Receivables for 8 consecutive years, with -$9182.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Interest Receivables rose 99.47% to -$9182.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $920743.0, a 39.28% increase, with the full-year FY2024 number at $1.3 million, up 195.98% from a year prior.
  • Change in Interest Receivables was -$9182.0 for Q3 2025 at Marker Therapeutics, up from -$784430.0 in the prior quarter.
  • In the past five years, Change in Interest Receivables ranged from a high of $1.6 million in Q4 2024 to a low of -$1.7 million in Q3 2024.
  • A 5-year average of $34978.6 and a median of $1948.0 in 2022 define the central range for Change in Interest Receivables.
  • Peak YoY movement for Change in Interest Receivables: surged 12016516.67% in 2022, then tumbled 67816.53% in 2023.
  • Marker Therapeutics' Change in Interest Receivables stood at -$6.0 in 2021, then soared by 12016516.67% to $720985.0 in 2022, then surged by 31.0% to $944502.0 in 2023, then surged by 69.64% to $1.6 million in 2024, then tumbled by 100.57% to -$9182.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Change in Interest Receivables are -$9182.0 (Q3 2025), -$784430.0 (Q2 2025), and $112062.0 (Q1 2025).